Ausgabe 1/2008
Inhalt (20 Artikel)
Third-line therapy for metastatic colorectal cancer
M. G. Gundgaard, J. B. Soerensen, E. Ehrnrooth
Modification of multidrug resistance of tumor cells by ionizing radiation
Yuri N. Korystov, Vera V. Shaposhnikova, Antonina F. Korystova, Maksim O. Emel’yanov, Ludmila N. Kublik
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers
Rob J. Jones, Tamsin Boyce, Michael Fennell, Vivien Jacobs, Francesco Pinto, Emma Duffield, Glen Clack, Tim Green, John Kelly, John Robertson
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin
Alfred F. Furth, Sumithra J. Mandrekar, Angelina D. Tan, Andrea Rau, Sara J. Felten, Matthew M. Ames, Alex A. Adjei, Charles Erlichman, Joel M. Reid
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
Jeeyun Lee, Tae-You Kim, Myung Ah Lee, Myung Ju Ahn, Hoon-Kyo Kim, Ho Yeong Lim, Nam Su Lee, Byung Joo Park, Jun Suk Kim
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer
Yoshihiro Wada, Ken Kikuchi, Wataru Takahashi, Jiro Honda, Juro Nakanishi, Koichiro Matsumoto, Tomohiro Kuwahara, Nobuyuki Kai, Hiroaki Kikukawa, Shoichi Ueda
Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
Lee Jia, Lori C. Coward, Corenna D. Kerstner-Wood, Ronda L. Cork, Gregory S. Gorman, Patricia E. Noker, Shinichi Kitada, Marrizio Pellecchia, John C. Reed
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
Sang Joon Shin, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Hei-Cheul Jeung, Sun Young Rha, Hyun Cheol Chung, Jae Kyung Roh
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus
Dae Ho Lee, Heung Tae Kim, Ji-Youn Han, Sung Young Lee, Sung Jin Yoon, Hyae Young Kim, Jin Soo Lee
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice
Roni Haklai, Galit Elad-Sfadia, Yaakov Egozi, Yoel Kloog
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction
Martina Baur, Anne Drescher, Margit Gneist, Christian Dittrich, Ulrich Jaehde
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin
Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili, Angela Sciandivasci, Rossana Tassi, Serenella Civitelli, Gabriello Tanzini, Marco Lorenzi, Guido Francini
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
G. Vassal, G. Michel, H. Espérou, J. C. Gentet, D. Valteau-Couanet, F. Doz, F. Mechinaud, C. Galambrun, B. Neven, H. Zouabi, L. Nguyen, C. Puozzo
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer
T. O’Connor, Y. Rustum, E. Levine, P. Creaven
Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin
Jaime A. Yáñez, M. Laird Forrest, Yusuke Ohgami, Glen S. Kwon, Neal M. Davies
Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria
N. A. G. Santos, C. S. Catão Bezerra, N. M. Martins, C. Curti, M. L. P. Bianchi, A. C. Santos
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert L. Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai, William Sherman, James Strauss, Susan Guba, Riolan Andrade, John Chabot
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert L. Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai, William Sherman, James Strauss, Susan Guba, Riolan Andrade, John Chabot